Search
Evolus Inc
EOLSAdd to Watchlist
6.615USD
-0.125-1.85%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
428.43MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Evolus Inc is 8.57, ranking 27 out of 157 in the Pharmaceuticals industry. The average price target is 19.50, with a high of 20.00 and a low of 14.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.667
Target Price
+117.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Evolus Inc
EOLS
7
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Evolus Inc's expected revenue for the next quarter?
Evolus Inc's expected revenue is 81.95M.
What is Evolus Inc's price target?
Analysts forecast that Evolus Inc's price target is USD 19.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 14.00.
What is the analyst rating for Evolus Inc?
Based on the ratings of Evolus Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
